ODAC
ODAC to FDA: More Study Needed Before Sintilimab Can be Approved in the U.S.
In a 14-to-1 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) said additional clinical trials with ...
FEBRUARY 10, 2022
FDA Advisory Committee Rejects Selinexor for MM, Wants More Data
The ODAC voted 8 to 5 recommending that the FDA wait for the results from the randomized, open-label, phase 3 ...
FEBRUARY 28, 2019
Load more